AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

October 28, 2016 7:44 AM EDT
Get Alerts ABBV Hot Sheet
Trade ABBV Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

AbbVie (NYSE: ABBV) reported Q3 EPS of $1.21, $0.01 better than the analyst estimate of $1.20. Revenue for the quarter came in at $6.43 billion versus the consensus estimate of $6.56 billion.

  • Global HUMIRA sales increased 11.3 percent on a reported basis. Operational HUMIRA sales increased 12.1 percent, excluding a 0.8 percent impact from foreign exchange. Strong global growth was driven by continued momentum across all three major market categories – rheumatology, dermatology and gastroenterology.
  • Third-quarter global IMBRUVICA net revenue was $501 million, with U.S. sales of $437 million and international profit sharing of $64 million for the quarter. Total company sales growth was also driven by strong operational growth from Creon and Duodopa.


AbbVie declared a quarterly dividend of $0.64 per share, or $2.56 annualized. This is a 12.3% increase from the prior dividend of $0.57 per share.

The dividend will be payable on February 15, 2017, to stockholders of record on January 13, 2017, with an ex-dividend date of January 11, 2017.

The annual yield on the dividend is 4.2 percent.


AbbVie sees FY2016 EPS of $4.00-$4.82, versus the consensus of $4.82.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Dividend Hike, Dividends, Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities


Add Your Comment